% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{OssamiSaidy:301519,
      author       = {A. Ossami Saidy and C. Peczynski and C. Thieblemont and M.
                      Daskalakis and M. Wehrli and D. Beauvais and J. Finke and E.
                      Schorb and P. Vandenberghe and P. Berning and M. Stelljes
                      and F. Ayuk and R. Ram and M. Von Bonin and P. Dreger and W.
                      Bethge and A. Kuhnl and L. Jost and F. Stölzel and B. von
                      Tresckow$^*$ and C. Renner and S. Fuhrmann and J.-E.
                      Galimard and E. Michel and A. Bazarbachi and A. S. Balari
                      and N. Schmitz and B. Glass},
      title        = {{E}fficacy and safety of {CAR} {T}-cell therapy in patients
                      with primary or secondary {CNS} lymphoma: {A} study on
                      behalf of the {EBMT} and the {G}o{CART} coalition.},
      journal      = {HemaSphere},
      volume       = {9},
      number       = {5},
      issn         = {2572-9241},
      address      = {Hoboken},
      publisher    = {John Wiley $\&$ Sons Ltd.},
      reportid     = {DKFZ-2025-01056},
      pages        = {e70146},
      year         = {2025},
      abstract     = {Patients with relapsed or refractory (r/r) primary central
                      nervous system (CNS) lymphoma (PCNSL) or secondary central
                      nervous system (CNS) lymphoma (SCNSL) face a dismal
                      prognosis. They have been excluded from most clinical CAR
                      T-cell trials as investigators feared an increased risk for
                      severe immune effector cell-associated neurotoxicity
                      (ICANS). To investigate the potential of anti-CD19 CAR
                      T-cell therapy (CART) in such patients, we analyzed data of
                      100 patients with CNS manifestation treated with CART
                      between January 2018 and July 2023 and reported to European
                      Society for Blood and Marrow Transplantation. Median age was
                      62 years. Of patients, $58\%$ had failed ≥3 treatment
                      lines, and $40\%$ had received autologous stem-cell
                      transplantation before CART. Fifty-nine patients received
                      axicabtagene ciloleucel, 38 patients were treated with
                      tisagenlecleucel, three patients received other products. At
                      the time of CART, 67 patients had active CNS disease.
                      Overall and progression-free survival (PFS) at 24 months
                      were $37\%$ and $28\%.$ Relapse incidence (RI) at 24 months
                      was $59\%,$ whereas non-relapse mortality at 1 year was
                      $7\%.$ Cytokine release syndrome (CRS) and ICANS of any
                      grade occurred in $83\%$ and $42\%$ of patients,
                      respectively. CRS grade 3 occurred in 11 and ICANS grades
                      3-4 in 17 patients. Two patients died of neurotoxicity.
                      Elevated lactate dehydrogenase was an independent risk
                      factor for RI and PFS (hazard ratio [HR] 2.4, p = 0.003; HR:
                      1.9, p = 0.016). Patients with ECOG 2-3 had a significantly
                      increased risk for the development of ICANS (HR 2.68, p =
                      0.002). These data support the implementation of CART as
                      treatment for patients with r/r PCNSL and SCNSL.},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40400509},
      pmc          = {pmc:PMC12093105},
      doi          = {10.1002/hem3.70146},
      url          = {https://inrepo02.dkfz.de/record/301519},
}